Toggle light / dark theme

Experimental weight-loss drug eases painful knee osteoarthritis in two clinical trials

For people with painful knee osteoarthritis (OA) who are overweight or have obesity, everyday activities such as walking, climbing stairs and standing up from a chair can be difficult. In two Northwestern University–led Phase III clinical trials involving more than 1,000 participants combined, those taking the highest dose of retatrutide, a new experimental weight-loss injectable drug, lost about one-quarter of their body weight on average.

A pooled analysis of the studies found that about two-thirds of participants receiving retatrutide experienced at least a 50% reduction in knee pain, compared with 38% of those receiving placebo.

In addition to weight loss and pain relief, participants experienced other significant benefits, including reduced blood pressure, lower lipid levels and less systemic inflammation.

Leave a Comment

Lifeboat Foundation respects your privacy! Your email address will not be published.